Table 4.
Subgroups analysis of ORR achievement
| Parameters | ORR (n = 75) | Not ORR (n = 24) | P value |
|---|---|---|---|
| Age (years) | 58.27 ± 10.09 | 57.04 ± 11.05 | |
| Gender Male (n/%) | 68 (76.4) | 21 (23.6) | 0.654 |
| HBV (n/%) | 71 (75.5) | 23 (24.5) | 0.820 |
| HCV (n/%) | 1 (50.0) | 1 (50.0) | 0.390 |
| Drink (n/%) | 33 (76.7) | 10 (23.3) | 0.841 |
| Cirrhosis (n/%) | 41 (74.5) | 14 (25.5) | 0.753 |
| Tumor distributiona | 0.765 | ||
| > =20% (n/%) | 38 (74.5) | 13 (25.5) | |
| < 20 (n/%) | 37 (77.1) | 11 (22.9) | |
| Number of nodules | |||
| 1 (n/%) | 26 (86.7) | 4 (13.3) | 0.095 |
| > 1 (n/%) | 49 (71.0) | 20 (29.0) | |
| < =3 (n/%) | 45 (83.3) | 9 (16.7) | 0.054 |
| > 3 (n/%) | 30 (66.7) | 15 (33.3) | |
| Largest nodule size > 3 cm (n/%) | 54 (78.3) | 15 (21.7) | 0.278 |
| Largest nodule size > 5 cm (n/%) | 33 (75.0) | 11 (25.0) | 0.875 |
| Portal vein invasion (n/%) | 19 (65.5) | 10 (34.5) | 0.126 |
| Main portal vein invasion (n/%) | 3 (37.5) | 5 (62.5) | 0.173 |
| First branch invasion (n/%) | 4 (50.0) | 4 (50.0) | |
| Second branch invasion (n/%) | 10 (76.9) | 3 (23.1) | |
| Hepatic vein invasion (n/%) | 12 (70.6) | 5 (29.4) | 0.585 |
| ECOG performance status | 0.595 | ||
| 0 (n/%) | 52 (74.3) | 18 (25.7) | |
| 1 (n/%) | 23 (79.3) | 6 (20.7) | |
| Child-pugh stage | 0.419 | ||
| A (n/%) | 68 (74.7) | 23 (25.3) | |
| B (n/%) | 7 (87.5) | 1 (12.5) | |
| BCLC stage | 0.029 | ||
| A (n/%) | 19 (79.2) | 5 (20.8) | |
| B (n/%) | 31 (88.6) | 4 (11.4) | |
| C (n/%) | 25 (62.5) | 15 (37.5) | |
| AFP | 0.432 | ||
| Abnormal (n/%) | 40 (72.7) | 15 (27.3) | |
| Normal (n/%) | 35 (79.5) | 9 (20.5) | |
| Previous cTACE | 0.089 | ||
| Yes (n/%) | 26 (66.7) | 13 (33.3) | |
| No (n/%) | 49 (81.7) | 11 (18.3) | |
| Previous surgery | 0.136 | ||
| Yes (n/%) | 53 (80.3) | 13 (19.7) | |
| No (n/%) | 22 (66.7) | 11 (33.3) | |
| Previous systematic chemotherapy | 0.820 | ||
| Yes (n/%) | 4 (80.0) | 1 (20.0) | |
| No (n/%) | 71 (75.5) | 23 (24.5) | |
| Previous radiofrequency ablation | 0.585 | ||
| Yes (n/%) | 12 (70.6) | 5 (29.4) | |
| No (n/%) | 63 (76.8) | 19 (23.2) | |
| Previous targeted therapy (n/%) | 0.562 | ||
| Yes (n/%) | 1 (100.0) | 0 (0.0) | |
| No (n/%) | 74 (75.5) | 24 (24.5) | |
| Chemoembolization reagent | 0.248 | ||
| Adriamycin (n/%) | 4 (100.0) | 0 (0.0) | |
| Epirubicin (n/%) | 71 (74.7) | 24 (25.3) | |
Data was presented as count (%) or mean ± standard deviation
Comparison between groups was determined by t test or Chi-square test. P < 0.05 was considered significant. aTumor distribution: percentage of tumor in the whole liver
HBV Hepatic b virus, HCV Hepatic c virus, ECOG Eastern Cooperative Oncology Group, BCLC Barcelona Clinic Liver Cancer, AFP Alpha fetal protein, cTACE Conventional transarterial chemo-embolization